Indian SARS-CoV-2 Genomic Consortia (INSACOG)

The government has launched the Indian SARS-CoV-2 Genomic Consortia (INSACOG), comprising 10 labs namely DBT-NIBMG Kalyani, DBT-ILS Bhubaneswar, ICMR-NIV Pune, DBT-NCCS Pune, CSIR-CCMB Hyderabad, DBT-CDFD Hyderabad, DBT-InSTEM/ NCBS Bengaluru, NIMHANS Bengaluru, CSIR-IGIB Delhi, and NCDC Delhi.

Features of Indian SARS-CoV-2 Genomics Consortium :

The overall aim of the Indian SARS-CoV-2 Genomics Consortium is to monitor the genomic variations in the SARS-CoV-2 on a regular basis through a multi-laboratory network. This vital research consortium will also assist in developing potential vaccines in the future. The consortium will ascertain the status of new variant of SARS-CoV-2 (SARS-CoV-2 VUI 202012/01) in the country, establish a sentinel surveillance for early detection of genomic variants with public health implication, and determine the genomic variants in the unusual events/trends (super-spreader events, high mortality/morbidity trend areas etc. Coordinated by Department of Biotechnology (DBT) along with MoH&FW, ICMR, and CSIR, the strategy and roadmap of the National SARS CoV2 Genome Sequencing Consortium (INSACOG) has been prepared.

SARS-CoV-2 Virus

ICTV announced “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” as the name of the new virus.
This name was chosen because the virus is genetically related to the coronavirus responsible for the SARS outbreak of 2003. While related, the two viruses are different.
In the backdrop of the emergence of a newly identified variant of the novel SARS-CoV-2 Virus in the UK, South Africa and some other parts of the world, the Government has taken action to accelerate VirusSurveillance, Genome Sequencing and Characterization.
A new variant, which that was found in the UK, especially in the London region, is defined by multiple mutations in the Spike region, as well as mutations in other genomic regions.
As per DBTDBT, these mutations are rapidly increasing the number of variants of the virus. This variant is significantly more transmissible than previously circulating variants, with an estimated potential to increase the reproductive number with an estimated increased transmissibility of up to 70%.
The Indian SARS-CoV-2 Genomics Consortium (INSACOG) will monitor the genomic variations on a regular basis through the multi-laboratory network.
Knowledge generated though this vital research consortium will also assist in developing diagnostics and potential therapeutics and vaccines in the future.

DBT-NIBMG

DBT-NIBMG as the Co-ordinating Unit of Genome Sequencing Consortium and will closely work with a Nodal Unit of NCDCon activities like SOPs, data annotation, data analysis, data release etc.
NCDC will maintain a database of all samples of the new variants of public health significance. The data will be epidemiologically analysed, interpreted and shared with state/district for investigation, contact tracing and planning response strategies.
All the genomic sequencing data will be maintained in a National database at two sites, DBT-NIBMG, Kalyani and CSIR-IGIB, New Delhi.
The virus isolated will be deposited in the notified SARS-CoV-2 virus repository etc RCB, Faridabad and NIV, Pune.

Source: PIB